FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results

European Journal of Cancer

Volumn 36, Issue 8, 2000, Pages 966-975

  Pacini, P ^a   Rinaldini, M ^b   Algeri, R ^c   Guarneri, A ^d   Tucci, E ^e   Barsanti, G ^f   Neri, B ^a   Bastiani, P ^g   Marzano, S ^h   Fallai, C ^a  

^a Policlin D   (Italy)

^b Ospedale Civile   (Italy)

^c Ospedale Civile   (Italy)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

^e Divisione Radioterapia Oncologica   (Italy)

^f Osp Campo di   (Italy)

^g Ospedale Civile   (Italy)

^h Sezione di Radioterapia Osp di C   (Italy)

Author keywords

Advanced breast cancer chemotherapy; Epidoxorubicin drug combination; Lonidamine and breast cancer; Lonidamine therapy; Mitomycin C drug combination

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; LONIDAMINE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; FEMALE; HISTOLOGY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SURVIVAL TIME; VOMITING;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 17444448833     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00068-X     Document Type: Article

References (35)

1. Zaffaroni N., Bearzatto A., Gornati D., Silvestrini R. Effect of lonidamine on the cytotoxic activity of cisplatin, mitomycin C and BCNU in human ovarian and colon carcinoma cells. Int. J. Oncol. 4:1994;773-778.
2. Forster R., Campana A., D'Onofrio E., Henderson L., Mosesso P., Scorza Barcellona P. Lonidamine. a non-mutagenic antitumor agent Carcinogenesis. 11:1990;1509-1515.
3. Zupi G., Greco C., Laudonio N., Benassi M., Silvestrini B., Caputo A. In vitro and in vivo potentiation by lonidamine of the antitumor effect of Adriamycin. Anticancer Res. 6:1986;1245-1250.
4. Floridi A., Paggi M.G., D'Atri S.et al. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J. Natl. Cancer Inst. 66:1981;497-499.
5. Silvestrini B., Hahn G.M., Cioli V.et al. Effects of Lonidamine alone or combined with hyperthermia in some experimental cell and tumor systems. Br. J. Cancer. 47:1983;221-231.
6. Band P.R., Maroun J., Pritchard K.et al. Phase II study of Lonidamine in patients with metastatic breast cancer. a National Cancer Institute of Canada Clinical Trials Group Study Cancer Treat Rep. 70:1986;1305-1310.
7. Amoroso D, Bertelli G, Gardin G, et al. Lonidamine in breast cancer: An update (abstract). Third IST International Symposium "Biology and Therapy of Breast Cancer. Genoa, 1989, 47.
8. De Graeff A, Mansi JL, Newell DR, Smith IE. A Phase II Study of Lonidamine in Advanced Breast Cancer. ECCO 5, London,1989, P-0972.
9. Mansi J.L., de Graeff A., Newell D.R.et al. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer. Br. J. Cancer. 64:1991;593-597.
10. Pronzato P., Amoroso D., Bertelli G.et al. Phase II study of lonidamine in metastatic breast cancer. Br. J. Cancer. 59:1989;251-253.
11. Robins I.H., Neuberg D.S., Benson A.B., Pandys K.J., Tormey D.C. Phase II study of lonidamine in patients with metastatic breast cancer. Invest. New Drugs. 8:1990;397-399.
12. Robustelli della Cuna G., Pedrazzoli P. Toxicity and clinical tolerance of Lonidamine. Semin. Oncol. 18:1991;18-22.
13. Rosso R., Amoroso D., Gardin G.et al. Lonidamine in metastatic cancer. Semin. Oncol. 18(Suppl. 4):1991;62-65.
14. Neri B., Lottini G., Bandinelli E., Cini-Neri G. Doxorubicin plus Lonidamine. in vivo metabolic effects on the rat heart Anti-Cancer Drugs. 2:1991;401-404.
15. Ambrosini G., Balli M., Garusi G.et al. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer. an Italian multicentre trial J. Clin. Oncol. 6:1988;976-982.
16. Chauvergne J., Durand M., Mauriac J.et al. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J. Clin. Oncol. 6:1988;679-688.
17. Garewal H.S. Mitomycin C in the chemotherapy of advanced breast cancer. Semin. Oncol. 15:1988;74-79.
18. Andersson M., Daugaard S., von der Maase H., Mouridsen H.T. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer. a randomized study Cancer Treat. Rep. 70:1986;1181-1186.
19. Amiel S.A., Stewart J.H., Earl H.M., Knight R.K., Rubens R.D. Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer. Eur. J. Cancer Clin. Oncol. 20:1984;631-634.
20. Harris M.A., Byrne P.J., Smith F.P.et al. Treatment of advanced breast cancer with two doxorubicin-containing regimens. Am. J. Clin. Oncol. 6:1984;51-58.
21. Pacini P., Tucci E., Algeri R.et al. Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. Eur. J. Cancer. 30A:1994;460-463.
22. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
23. Alexander J., Dainiak N., Berger H.J.et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N. Engl. J. Med. 300:1979;278-283.
24. Lopez M., Vici P., Di Lauro L.et al. Intrapatient comparison of single agent Epirubicin with or without Lonidamine in metastatic breast cancer. Eur. J. Cancer. 31A:1995;1611-1614.
25. Tomirotti M., Bernardo G., Epifani C.et al. Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients. Int. J. Oncol. 3:1993;213-217.
26. Moraglio L., Brema F., Pastorino G., Martini M.C., Vallauri M. Combination of epirubicin and lonidamine for treatment of advanced breast cancer. Tumori. 81:1995;107-111.
27. Gardin G., Barone C., Nascimbene O.et al. Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study. Eur J Cancer. 32A:1996;176-177.
28. Gebbia V., Borsellino N., Testa A.et al. Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer. a phase study of the Southern Italy Oncology Group (GOIM) Anticancer Drugs. 8:1997;943-948.
29. Dogliotti L., Danese S., Berruti A.et al. Cisplatin, epirubicin, and lonidamine combination regimen as first line chemotherapy for metastatic breast cancer. a pilot study Cancer Chemother. Pharmacol. 41:1998;333-338.
30. Amadori D., Frassineti G.L., de Matteis A.et al. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients. Results from a multicenter prospective randomized trial. Breast Cancer Res. Treat. 49:1998;209-217.
31. Dogliotti L., Berruti A., Buniva T.et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer. Results from a multicenter prospective randomized trial. J. Clin. Oncol. 14:1996;1165-1172.
32. Lorusso V., Catino A., Brandi M.et al. Cyclophosphamide, mitoxantrone and fluorouracil versus cyclophosphamide, mitoxantrone and fluorouracil plus lonidamine for the treatment of advanced breast cancer. A multicentric randomized clinical trial. Int. J. Oncol. 4:1994;767-772.
33. Calabresi F., Marolla P., Di Lauro L.et al. Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. results of a multicentric randomized clinical study Int. J. Oncol. 4:1994;753-760.
34. Calabresi F. Drug resistance. Lonidamine PPO Updates. 8:1994;1-15.
35. Pacini P., Algeri R., Rinaldini M.et al. FEC (fluorouracil, epirubicin and cyclophosphamide) versus EM (epirubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. a multicentric randomized study. Preliminary report Int. J. Oncol. 4:1994;761-766.